<DOC>
	<DOC>NCT01012232</DOC>
	<brief_summary>In a randomized, double-blind, cross-over trial, 48 patients scheduled for total knee arthroplasty with placement of an intracapsular catheter will be randomized to receive bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL) or low volume/high concentration (10 mL, 10 mg/mL) 6 and 24 hours postoperatively, and pain will be assessed at rest and with mobilization for 2 hours after injections.</brief_summary>
	<brief_title>Local Anesthetic in Total Knee Arthroplasty (TKA): Volume Versus Concentration</brief_title>
	<detailed_description />
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Ropivacaine</mesh_term>
	<mesh_term>Anesthetics, Local</mesh_term>
	<criteria>Scheduled for total knee arthroplasty Able to give informed oral and written consent to participate Treatment with opioids or steroids, rheumatoid arthritis or other immunological diseases History of stroke or any neurological or psychiatric disease potentially influencing pain perception (e.g. depression, diabetic neuropathy etc.) Allergies to any of the drugs administered.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>total knee arthroplasty</keyword>
	<keyword>postoperative pain</keyword>
</DOC>